NCT06428331View on ClinicalTrials.gov

A Study of SKB518 in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

SKB518 for injection

SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

All Listed Sponsors

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY

NCT06428331 - A Study of SKB518 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter